|1.36||+0.2000||+17.24%||Vol 6.19M||1Y Perf -86.29%|
|Jun 24th, 2022 16:00 DELAYED|
|- -||0.07 5.15%|
|Target Price||5.00||Analyst Rating||Hold 3.00|
|Potential %||267.65||Finscreener Ranking||★★★★ 53.49|
|Insiders Trans % 3/6/12 mo.||-100/50/78||Value Ranking||★★ 46.03|
|Insiders Value % 3/6/12 mo.||-100/88/98||Growth Ranking||★★★★ 60.59|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/57/93||Income Ranking||— -|
|Price Range Ratio 52W %||9.77||Earnings Rating||Strong Buy|
|Market Cap||108.03M||Earnings Date||4th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Aug 2022|
|Estimated EPS Next Report||-0.33|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.52M|
|Avg. Monthly Volume||1.88M|
|Avg. Quarterly Volume||1.05M|
Accelerate Diagnostics Inc. (NASDAQ: AXDX) stock closed at 1.36 per share at the end of the most recent trading day (a 17.24% change compared to the prior day closing price) with a volume of 6.19M shares and market capitalization of 108.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 275 people. Accelerate Diagnostics Inc. CEO is John Phillips.
The one-year performance of Accelerate Diagnostics Inc. stock is -86.29%, while year-to-date (YTD) performance is -73.95%. AXDX stock has a five-year performance of -95.5%. Its 52-week range is between 0.502 and 9.28, which gives AXDX stock a 52-week price range ratio of 9.77%
Accelerate Diagnostics Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 89.93, a price-to-sale (PS) ratio of 5.65, a price to cashflow ratio of 213.80, a PEG ratio of 2.32, a ROA of -82.99%, a ROC of -51.28% and a ROE of 109.87%. The company’s profit margin is -%, its EBITDA margin is -431.60%, and its revenue ttm is $12.22 Million , which makes it $0.15 revenue per share.
Of the last four earnings reports from Accelerate Diagnostics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.33 for the next earnings report. Accelerate Diagnostics Inc.’s next earnings report date is 04th Aug 2022.
The consensus rating of Wall Street analysts for Accelerate Diagnostics Inc. is Hold (3), with a target price of $5, which is +267.65% compared to the current price. The earnings rating for Accelerate Diagnostics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Accelerate Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Accelerate Diagnostics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.07, ATR14 : 0.18, CCI20 : 206.10, Chaikin Money Flow : 0.19, MACD : 0.09, Money Flow Index : 84.80, ROC : 18.26, RSI : 70.70, STOCH (14,3) : 81.25, STOCH RSI : 1.00, UO : 64.60, Williams %R : -18.75), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Accelerate Diagnostics Inc. in the last 12-months were: Hany Massarany (Buy at a value of $119 000), Jack Phillips (Option Excercise at a value of $0), Jack Phillips (Sold 115 559 shares of value $119 603 ), Jack W Schuler (Buy at a value of $10 470 125), Jack W. Schuler (Buy at a value of $10 470 125), Ron Price (Option Excercise at a value of $0), Ron Price (Sold 15 072 shares of value $14 771 ), Steven Reichling (Option Excercise at a value of $0), Steven Reichling (Sold 29 915 shares of value $29 317 )
Sat, 19 Mar 2022 09:11 GMT Accelerate Diagnostics (AXDX) Gets a Hold Rating from BTIG- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.